Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

4.52USD
13 Dec 2018
Change (% chg)

$0.19 (+4.39%)
Prev Close
$4.33
Open
$4.34
Day's High
$4.64
Day's Low
$4.34
Volume
1,100,288
Avg. Vol
1,007,352
52-wk High
$33.61
52-wk Low
$3.55

Select another date:

Fri, Dec 7 2018

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

REFILE-UPDATE 2-Delaware judge says Fresenius can walk away from $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

Fresenius shares jump on report of win in Akorn ruling

LONDON Shares in German healthcare group Fresenius surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn .

Judge invokes inherent power to police mootness fees in M&A challenge

The class action watchdogs at the Competitive Enterprise Institute lost a battle this week in their challenge to a $322,500 mootness fee for shareholders' lawyers who sued over Akorn Corporation’s M&A deal with Fresenius Kabi AG. U.S. District Judge Thomas Durkin of Chicago denied a motion by CEI’s Ted Frank, an Akorn shareholder, to intervene in litigation in which Akorn agreed to pay the fee. Judge Durkin rejected CEI’s argument that Frank has an interest, as a shareholder, in assu

Select another date: